Sign inJoin waitlistJoin the waitlist

Christine Baik

Clinical Research Director, Thoracic, Head and Neck Oncology, UW Medicine · University of Washington School of Medicine

Credentials: · · · · ·

History

Thoracic · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
Tufts Medical Center
2005–2008
Internal Medicine
Brown University
2002–2005
Harvard School of Public Health
University of Rochester School of Medicine and Dentistry
1998–2002

Research

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
The Lancet Oncology · 2016 · 692 citations
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
The Lancet Oncology · 2021 · 362 citations

Keith Eaton
18 papers
RD
Rafael Santana Davila
17 papers
Renato Martins
17 papers
Sylvia Lee
16 papers
Cristina Rodriguez
12 papers
LC
Laura Chow
12 papers
Aaron Mansfield
9 papers
BG
Bernardo Goulart
9 papers
Xiuning Le
9 papers
Jonathan Riess
6 papers
JG
Justin Gainor
6 papers
McGarry Houghton
6 papers

Clinical trials

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Principal investigator · Recruiting · Phase 2
University of Washington
2026–2031
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 2
University of Washington
2023–2028
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
Principal investigator · Completed · Phase 2
University of Washington
2012–2019
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Site PI · Recruiting · Phase 3
Nuvalent Inc.
2025–2029